Several other research analysts also recently commented on SNES. Zacks Investment Research downgraded shares of SenesTech from a hold rating to a sell rating in a research note on Tuesday, October 3rd. Craig Hallum set a $3.00 price objective on shares of SenesTech and gave the company a buy rating in a research report on Wednesday, November 22nd.
SenesTech (NASDAQ SNES) opened at $0.72 on Thursday. The company has a current ratio of 2.94, a quick ratio of 2.67 and a debt-to-equity ratio of 0.17. SenesTech has a one year low of $0.56 and a one year high of $10.69.
A number of institutional investors have recently modified their holdings of the business. Gilder Gagnon Howe & Co. LLC increased its position in SenesTech by 3.0% during the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,078,499 shares of the company’s stock valued at $1,995,000 after purchasing an additional 31,330 shares during the period. TCI Wealth Advisors Inc. purchased a new position in SenesTech during the 3rd quarter valued at $748,000. Skylands Capital LLC increased its position in SenesTech by 139.8% during the 3rd quarter. Skylands Capital LLC now owns 87,483 shares of the company’s stock valued at $162,000 after purchasing an additional 51,000 shares during the period. Prudential PLC increased its position in SenesTech by 49.3% during the 2nd quarter. Prudential PLC now owns 447,971 shares of the company’s stock valued at $2,661,000 after purchasing an additional 147,971 shares during the period. Finally, White Pine Capital LLC purchased a new position in SenesTech during the 2nd quarter valued at $110,000. 14.44% of the stock is currently owned by institutional investors and hedge funds.
SenesTech Company Profile
SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.